Mild to moderate plaque psoriasis

Indication for Tazarotene

Population group: Suitable for both men and women, only adults (18 - 65 years old)

Tazarotene is indicated for the topical treatment of mild to moderate plaque psoriasis involving up to 10% body surface area.

For this indication, competent medicine agencies globally authorize below treatments:

1 spread once a day

Route of admnistration


Defined daily dose

1 - 1 {spreads}

Dosage regimen

From 1 To 1 {spreads} once every day

Detailed description

A thin film of the gel should be applied once daily in the evening; care should be taken to apply it only to areas of affected skin, avoiding application to healthy skin or in skin folds. Treatment is limited to 10% body surface area (approximately equivalent to the total skin area of one arm).

If the patient experiences more drying or irritation, an effective greasy emollient (without pharmaceutically active ingredients) can be applied to the areas of the skin to be treated to improve tolerability. Healthy skin around the psoriatic plaques can be covered by using zinc paste, for example, to prevent irritation.

Usually, the treatment period is up to 12 weeks. Clinical experience, particularly on tolerability, is available on periods of use of up to 12 months.

Active ingredient

Tazarotene, a member of the acetylenic class of retinoids, is a prodrug which is converted to its active free form, tazarotenic acid, by de-esterification in the skin area. Tazarotenic acid is the only known metabolite of tazarotene to have retinoid activity.

Read more about Tazarotene

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner